Tradestie Institutional Equity Comparison Engine
TECH vs SYRE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TECH Overall Edge
TECH Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bio-Techne Corp. (TECH) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, TECH trades at 42.8x Forward P/E with 21.7% operating margin (+4.6% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, TECH sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
TECH
TECH 42.8x vs SYRE N/M Fwd P/E
Growth & Margin Winner
TECH
Op Margin 21.7% vs 0.0% ยท YoY +4.6% vs +0.0%
Momentum & Technical Winner
TECH
1Y +19.8% vs +341.7% ยท 52W Pos 100% vs 88%
Options & Structure Winner
TECH
UNCLASSIFIED (6th %ile IV) vs UNCLASSIFIED (10th %ile IV)
TECH
NASDAQ
Bio-Techne Corp.
Biological Products, (No Disgnostic Substances)
$72.79
-0.01% 1D
Market Cap
$11.4B
1M Return
+0.3%
1Y Return
+19.82%
Forward P/E
42.8x
Unified AI Score
53.1 / 100
HOLD
Tech 43.0
Fund 46.0
Flow 50.0
Mom 50.0
SYRE
NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap
$9.8B
1M Return
+25.11%
1Y Return
+341.74%
Forward P/E
N/M
Unified AI Score
44.4 / 100
HOLD
Tech 31.0
Fund 33.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
TECH +19.82%
SYRE +341.74%
Spread: +321.92 pp (SYRE Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
TECH TTM Op. Margin: 21.7%
SYRE TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TECH vs SYRE. Trailing 12-month operating profitability (TECH 21.7% vs SYRE 0.0%) and valuation multiples (TECH 42.8x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TECH | SYRE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $11.4B | $9.8B | Larger Scale | TECH |
| Trailing P/E Ratio Valuation | 66.8x | N/M | Lower Multiple | TECH |
| Forward P/E Ratio Valuation | 42.8x | N/M | Lower Multiple | TECH |
| Revenue Growth (YoY) Growth | +4.6% | +0.0% | Higher Growth | TECH |
| Operating Margin (TTM) Profitability | 21.7% | 0.0% | Higher Margin | TECH |
| Net Profit Margin Profitability | 14.0% | 0.0% | Higher Margin | TECH |
| Return on Equity (ROE) Capital Efficiency | 8.3% | -35.0% | Higher ROE | TECH |
| 52-Week Range Position Momentum | 100% ($43โ$73) | 88% ($22โ$111) | Stronger Trend | TECH |
| Beta / 30D Volatility Risk Regime | 0.37ฮฒ ยท 1% Vol | 1.75ฮฒ ยท 59% Vol | Lower Realized Risk | TECH |
| Unified Institutional Score Composite Signal | 53.1 / 100 (HOLD) | 44.4 / 100 (HOLD) | Higher Composite | TECH |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full TECH vs SYRE Buy Guide
TECH
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
SYRE
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither TECH nor SYRE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.